Cargando…

Gavi HPV Programs: Application to Implementation

Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an oppor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanson, Celina M., Eckert, Linda, Bloem, Paul, Cernuschi, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494350/
https://www.ncbi.nlm.nih.gov/pubmed/26343194
http://dx.doi.org/10.3390/vaccines3020408
_version_ 1782380075673452544
author Hanson, Celina M.
Eckert, Linda
Bloem, Paul
Cernuschi, Tania
author_facet Hanson, Celina M.
Eckert, Linda
Bloem, Paul
Cernuschi, Tania
author_sort Hanson, Celina M.
collection PubMed
description Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings.
format Online
Article
Text
id pubmed-4494350
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44943502015-08-31 Gavi HPV Programs: Application to Implementation Hanson, Celina M. Eckert, Linda Bloem, Paul Cernuschi, Tania Vaccines (Basel) Review Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings. MDPI 2015-05-20 /pmc/articles/PMC4494350/ /pubmed/26343194 http://dx.doi.org/10.3390/vaccines3020408 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hanson, Celina M.
Eckert, Linda
Bloem, Paul
Cernuschi, Tania
Gavi HPV Programs: Application to Implementation
title Gavi HPV Programs: Application to Implementation
title_full Gavi HPV Programs: Application to Implementation
title_fullStr Gavi HPV Programs: Application to Implementation
title_full_unstemmed Gavi HPV Programs: Application to Implementation
title_short Gavi HPV Programs: Application to Implementation
title_sort gavi hpv programs: application to implementation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494350/
https://www.ncbi.nlm.nih.gov/pubmed/26343194
http://dx.doi.org/10.3390/vaccines3020408
work_keys_str_mv AT hansoncelinam gavihpvprogramsapplicationtoimplementation
AT eckertlinda gavihpvprogramsapplicationtoimplementation
AT bloempaul gavihpvprogramsapplicationtoimplementation
AT cernuschitania gavihpvprogramsapplicationtoimplementation